04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
16:11 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology; autoimmune disease

INDICATION: Alzheimer’s disease (AD); multiple sclerosis (MS); rheumatoid arthritis (RA) Patient sample, in vitro , cell culture and mouse studies identified a peptide-based inhibitor of the MYD88-TLR2 interaction that could help treat AD, MS, and...
21:18 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies identified nine S. aureus and host factors as targets for treatment of dermatitis associated with S. aureus infections. In primary mouse and human keratinocytes treated with supernatants from S. aureus cultures,...
16:44 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; lung cancer; osteosarcoma; solid tumors Cell culture and mouse studies suggest chimeric antigen receptor (CAR) T cells engineered to express an MYD88 / CD40 -based construct could help treat osteosarcoma and other...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

BGB-3111: Ph III started

BeiGene began an international Phase III trial of 160 mg oral BGB-3111 twice daily in about 170 relapsed or refractory or treatment-naïve patients. The trial will compare BGB-3111 vs. once-daily 420 mg Imbruvica ibrutinib in...
19:34 , Dec 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Patient sample, cell culture and mouse studies suggest inhibiting MYD88 could help treat atopic and allergic dermatitis. In patient skin lesion samples, levels of MYD88 were higher and levels of its upstream signaling...
19:11 , Nov 17, 2016 |  BC Innovations  |  Translation in Brief

Point taken

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has identified an siRNA-like mechanism that may explain the unexpected potency and pinpoint specificity of its third-generation antisense (3GA) DNA technology, which allows for selective silencing of disease-causing alleles. Antisense oligonucleotides...
07:00 , Oct 10, 2016 |  BioCentury  |  Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...
07:00 , Oct 6, 2016 |  BC Innovations  |  Targets & Mechanisms

Seeking cysteines

In settling the question of how Biogen Inc. 's Tecfidera dimethyl fumarate (DMF) acts in multiple sclerosis, a Scripps team has identified PKCθ as a key driver, sitting atop an NF-κB pathway to immunosuppression. The...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Making sense of sensors

Two new pathways are emerging as viable options for harnessing nucleic acid sensors in immuno-oncology, offering an alternative to the toll-like receptors (TLRs) that paved the way. By activating STING or RIG-I , researchers are...